candesartan has been researched along with Obesity in 29 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with hypertension and obesity showing insulin resistance, treatment with telmisartan significantly improved the hyperinsulin response to glucose loading." | 9.15 | Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). ( Matsuura, K; Mori, Y; Tanaka, T; Utsunomiya, K; Yokoyama, J, 2011) |
| "We compared the effects of telmisartan with those of candesartan, on insulin sensitivity, the serum levels of various adipocytokines and oxidative stress." | 9.14 | Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. ( Awata, T; Ikebukuro, K; Inukai, K; Ito, D; Katayama, S; Kurihara, S; Ono, H; Sumita, T; Watanabe, M, 2010) |
| " The aim of this study was to investigate whether weight reduction after AT(1)-blockade is dependent on dose, blood pressure reduction and leptin signalling." | 7.77 | Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure. ( Jöhren, O; Markert, A; Müller-Fielitz, H; Pahlke, F; Raasch, W; Wittmershaus, C, 2011) |
| " While taking candesartan for hypertension, a 53-year-old woman with known ACE inhibitor intolerance developed angioedema." | 7.71 | Angioedema associated with candesartan. ( Lo, KS, 2002) |
| "Insulin sensitivity was expressed as insulin resistance index (IRI), calculated as the ratio of the area under the curve (AUC) for glucose to that for insulin." | 6.71 | Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. ( Bombelli, M; Dell'Oro, R; Facchini, A; Grassi, G; Mancia, G; Scopelliti, F; Seravalle, G; Trevano, FQ, 2003) |
| "In candesartan-treated db/db mice (1 mg/kg per day, 4 weeks) increased plasma aldosterone, CYP11B2 expression, and aldosterone secretion were reduced." | 5.38 | Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. ( Briones, AM; Burger, D; Burns, KD; Callera, GE; Corrêa, JW; Gagnon, AM; Gomez-Sanchez, CE; Gomez-Sanchez, EP; He, Y; Nguyen Dinh Cat, A; Ooi, TC; Ruzicka, M; Sorisky, A; Touyz, RM; Yogi, A, 2012) |
| "Obesity has been strongly associated with the development and aggravation of hypertension and chronic kidney disease." | 5.36 | Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats. ( Chang, YS; Chung, HW; Chung, S; Kim, BS; Kim, GH; Kim, HW; Lee, JH; Lim, JH; Park, CW; Shin, SJ; Youn, DY, 2010) |
| "Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity." | 5.36 | Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010) |
| "Candesartan was orally administered to 12-week-old rats for 21 days, and age-matched rats without the agent were used as the respective controls." | 5.31 | Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats. ( Daimon, M; Hirata, A; Igarashi, M; Kato, T; Ohnuma, H; Tominaga, M; Tsuchiya, H; Yamaguchi, H, 2001) |
| "A combination of a calcium channel blocker and angiotensin receptor blocker (lacidipine 2 mg, 4 mg, and candesartan 4mg, 8mg, 16mg) was prescribed to 30 patients with essential hypertension of grades 1-3, 30 to 65 years old (mean age - 54." | 5.27 | Beneficial effects of combined therapy with lacidipine and candesartan in obese hypertensive patients. ( Ashcheulova, T; Gerasimchuk, N; Honchar, O; Kovalyova, O, 2018) |
| "The present study by using the telemedicine system clearly demonstrated that telmisartan has a strong effect on reducing morning home BP, and a good effect on lipid metabolism in patients with metabolic syndrome." | 5.19 | Effectiveness of using long-acting angiotensin II type 1 receptor blocker in Japanese obese patients with metabolic syndrome on morning hypertension monitoring by using telemedicine system (FUJIYAMA study). ( Kinoshita, S; Nakamoto, H; Nishida, E; Ryuzaki, M; Sone, M, 2014) |
| "In patients with hypertension and obesity showing insulin resistance, treatment with telmisartan significantly improved the hyperinsulin response to glucose loading." | 5.15 | Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). ( Matsuura, K; Mori, Y; Tanaka, T; Utsunomiya, K; Yokoyama, J, 2011) |
| "The reduction in proteinuria induced by lisinopril (11." | 5.14 | [The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ]. ( Gutiérrez Solís, E; Gutiérrez, E; Huerta, A; Morales, E; Praga, M; Segura, J, 2009) |
| "We compared the effects of telmisartan with those of candesartan, on insulin sensitivity, the serum levels of various adipocytokines and oxidative stress." | 5.14 | Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. ( Awata, T; Ikebukuro, K; Inukai, K; Ito, D; Katayama, S; Kurihara, S; Ono, H; Sumita, T; Watanabe, M, 2010) |
| " CD-fed SHR were simultaneously treated with either telmisartan (TEL; 8 mg/kg(body weight)· d) or candesartan (CAND; 10 mg/kg(body weight)· d) for 3 months because TEL, but not CAND, has been demonstrated to be a strong activator of PPARγ." | 3.78 | Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARγ target gene regulation. ( Heidbreder, M; Jöhren, O; Landolt, J; Müller-Fielitz, H; Raasch, W; Vogt, FM; Werth, S, 2012) |
| " The aim of this study was to investigate whether weight reduction after AT(1)-blockade is dependent on dose, blood pressure reduction and leptin signalling." | 3.77 | Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure. ( Jöhren, O; Markert, A; Müller-Fielitz, H; Pahlke, F; Raasch, W; Wittmershaus, C, 2011) |
| " While taking candesartan for hypertension, a 53-year-old woman with known ACE inhibitor intolerance developed angioedema." | 3.71 | Angioedema associated with candesartan. ( Lo, KS, 2002) |
| "Insulin sensitivity was expressed as insulin resistance index (IRI), calculated as the ratio of the area under the curve (AUC) for glucose to that for insulin." | 2.71 | Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. ( Bombelli, M; Dell'Oro, R; Facchini, A; Grassi, G; Mancia, G; Scopelliti, F; Seravalle, G; Trevano, FQ, 2003) |
| "Treatment with amlodipine, candesartan, or indapamide did not significantly affect plasma visfatin levels." | 1.43 | Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations. ( Piecha, G; Skoczylas, A; Więcek, A, 2016) |
| "In candesartan-treated db/db mice (1 mg/kg per day, 4 weeks) increased plasma aldosterone, CYP11B2 expression, and aldosterone secretion were reduced." | 1.38 | Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. ( Briones, AM; Burger, D; Burns, KD; Callera, GE; Corrêa, JW; Gagnon, AM; Gomez-Sanchez, CE; Gomez-Sanchez, EP; He, Y; Nguyen Dinh Cat, A; Ooi, TC; Ruzicka, M; Sorisky, A; Touyz, RM; Yogi, A, 2012) |
| "Obesity has been strongly associated with the development and aggravation of hypertension and chronic kidney disease." | 1.36 | Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats. ( Chang, YS; Chung, HW; Chung, S; Kim, BS; Kim, GH; Kim, HW; Lee, JH; Lim, JH; Park, CW; Shin, SJ; Youn, DY, 2010) |
| "Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity." | 1.36 | Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010) |
| "The metabolic syndrome is a risk factor for the development of chronic kidney disease." | 1.35 | Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet. ( Haruna, Y; Kashihara, N; Kobayashi, S; Komai, N; Namikoshi, T; Sasaki, T; Satoh, M; Tomita, N, 2008) |
| "Candesartan was orally administered to 12-week-old rats for 21 days, and age-matched rats without the agent were used as the respective controls." | 1.31 | Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats. ( Daimon, M; Hirata, A; Igarashi, M; Kato, T; Ohnuma, H; Tominaga, M; Tsuchiya, H; Yamaguchi, H, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (37.93) | 29.6817 |
| 2010's | 18 (62.07) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashcheulova, T | 1 |
| Gerasimchuk, N | 1 |
| Kovalyova, O | 1 |
| Honchar, O | 1 |
| Kinoshita, S | 1 |
| Ryuzaki, M | 1 |
| Sone, M | 1 |
| Nishida, E | 1 |
| Nakamoto, H | 1 |
| Luo, H | 1 |
| Wang, X | 3 |
| Chen, C | 1 |
| Wang, J | 1 |
| Zou, X | 1 |
| Li, C | 1 |
| Xu, Z | 1 |
| Yang, X | 1 |
| Shi, W | 1 |
| Zeng, C | 1 |
| Takahashi, F | 1 |
| Goto, M | 1 |
| Wada, Y | 1 |
| Hasebe, N | 1 |
| Skoczylas, A | 1 |
| Piecha, G | 1 |
| Więcek, A | 1 |
| Namikoshi, T | 1 |
| Tomita, N | 1 |
| Satoh, M | 1 |
| Haruna, Y | 1 |
| Kobayashi, S | 1 |
| Komai, N | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Clodi, M | 1 |
| Resl, M | 1 |
| Stelzeneder, D | 1 |
| Pacini, G | 1 |
| Tura, A | 1 |
| Mörtl, D | 1 |
| Struck, J | 1 |
| Morgenthaler, NG | 1 |
| Bergmann, A | 1 |
| Riedl, M | 1 |
| Anderwald-Stadler, M | 1 |
| Luger, A | 1 |
| Pacher, R | 1 |
| Hülsmann, M | 1 |
| Hu, J | 1 |
| Tiwari, S | 3 |
| Riazi, S | 2 |
| Hu, X | 2 |
| Ecelbarger, CM | 4 |
| Yamauchi, T | 1 |
| Kadowaki, T | 1 |
| Chung, S | 1 |
| Park, CW | 1 |
| Shin, SJ | 1 |
| Lim, JH | 1 |
| Chung, HW | 1 |
| Youn, DY | 1 |
| Kim, HW | 1 |
| Kim, BS | 1 |
| Lee, JH | 1 |
| Kim, GH | 1 |
| Chang, YS | 1 |
| Morales, E | 1 |
| Huerta, A | 1 |
| Gutiérrez, E | 1 |
| Gutiérrez Solís, E | 1 |
| Segura, J | 1 |
| Praga, M | 1 |
| Fukuda, M | 1 |
| Nakamura, T | 1 |
| Kataoka, K | 1 |
| Nako, H | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Nakao, K | 1 |
| Hirata, M | 1 |
| Oba, K | 1 |
| Yasuno, S | 1 |
| Ueshima, K | 1 |
| Fujimoto, A | 1 |
| Ogihara, T | 1 |
| Saruta, T | 1 |
| Rash, A | 1 |
| Sinha, RK | 1 |
| Barrios, V | 1 |
| Escobar, C | 1 |
| Calderon, A | 1 |
| Li, F | 1 |
| Jose, PA | 1 |
| Watanabe, M | 1 |
| Inukai, K | 1 |
| Sumita, T | 1 |
| Ikebukuro, K | 1 |
| Ito, D | 1 |
| Kurihara, S | 1 |
| Ono, H | 1 |
| Awata, T | 1 |
| Katayama, S | 1 |
| Yan, WH | 1 |
| Pan, CY | 1 |
| Dou, JT | 1 |
| Ma, FL | 1 |
| Wang, XM | 1 |
| Yang, GQ | 1 |
| Wang, XL | 1 |
| Mu, YM | 1 |
| Lu, JM | 1 |
| Müller-Fielitz, H | 2 |
| Markert, A | 1 |
| Wittmershaus, C | 1 |
| Pahlke, F | 1 |
| Jöhren, O | 2 |
| Raasch, W | 2 |
| Mori, Y | 1 |
| Tanaka, T | 1 |
| Matsuura, K | 1 |
| Yokoyama, J | 1 |
| Utsunomiya, K | 1 |
| Landolt, J | 1 |
| Heidbreder, M | 1 |
| Werth, S | 1 |
| Vogt, FM | 1 |
| Eppel, GA | 1 |
| Head, GA | 1 |
| Denton, KM | 1 |
| Evans, RG | 1 |
| Briones, AM | 1 |
| Nguyen Dinh Cat, A | 1 |
| Callera, GE | 1 |
| Yogi, A | 1 |
| Burger, D | 1 |
| He, Y | 1 |
| Corrêa, JW | 1 |
| Gagnon, AM | 1 |
| Gomez-Sanchez, CE | 1 |
| Gomez-Sanchez, EP | 1 |
| Sorisky, A | 1 |
| Ooi, TC | 1 |
| Ruzicka, M | 1 |
| Burns, KD | 1 |
| Touyz, RM | 1 |
| Lo, KS | 1 |
| Grassi, G | 1 |
| Seravalle, G | 1 |
| Dell'Oro, R | 1 |
| Trevano, FQ | 1 |
| Bombelli, M | 1 |
| Scopelliti, F | 1 |
| Facchini, A | 1 |
| Mancia, G | 1 |
| Hakam, AC | 1 |
| Hussain, T | 1 |
| Kotovskaia, IuV | 1 |
| Kobalava, ZhD | 1 |
| Madala Halagappa, VK | 1 |
| Igarashi, M | 1 |
| Hirata, A | 1 |
| Yamaguchi, H | 1 |
| Tsuchiya, H | 1 |
| Ohnuma, H | 1 |
| Tominaga, M | 1 |
| Daimon, M | 1 |
| Kato, T | 1 |
1 review available for candesartan and Obesity
| Article | Year |
|---|---|
[Anti-metabolic syndrome effects of candesartan].
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; D | 2009 |
8 trials available for candesartan and Obesity
| Article | Year |
|---|---|
Beneficial effects of combined therapy with lacidipine and candesartan in obese hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Case-Control Studies; Dihy | 2018 |
Effectiveness of using long-acting angiotensin II type 1 receptor blocker in Japanese obese patients with metabolic syndrome on morning hypertension monitoring by using telemedicine system (FUJIYAMA study).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Benzimidazoles | 2014 |
Interactions of glucose metabolism and chronic heart failure.
Topics: Benzimidazoles; Benzoates; Biomarkers; Biphenyl Compounds; Blood Glucose; Blood Pressure; Chronic Di | 2009 |
[The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2009 |
Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2010 |
Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; B | 2011 |
Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2003 |
[Is primary prevention of arterial hypertension with drugs possible? Results of the TROPHY Study].
Topics: Benzimidazoles; Biphenyl Compounds; Cholesterol, LDL; Female; Humans; Hypertension; Male; Middle Age | 2006 |
20 other studies available for candesartan and Obesity
| Article | Year |
|---|---|
Oxidative stress causes imbalance of renal renin angiotensin system (RAS) components and hypertension in obese Zucker rats.
Topics: Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cyclic N-Oxides; Disease | 2015 |
Successful Treatment with an Antihypertensive Drug Regimen Including Eplerenone in a Patient with Malignant Phase Hypertension with Renal Failure.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cal | 2015 |
Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; | 2016 |
Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dietary Protei | 2008 |
Regulation of angiotensin II type I receptor (AT1R) protein levels in the obese Zucker rat kidney and urine.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biomarker | 2009 |
Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Antioxidants; Benzimidazoles; Biphenyl Compounds; Cyclic N-Oxides; | 2010 |
Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2010 |
Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2010 |
The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cytokines; Die | 2010 |
Cardiovascular protection with candesartan in patients with metabolic disorders.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2010 |
Reduction of renal dopamine receptor expression in obese Zucker rats: role of sex and angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2010 |
[Effects of candesartan on expressions of JAK2 and PTP-1B in adipose tissue of high-fat diet-fed rats].
Topics: Adipose Tissue; Animals; Benzimidazoles; Biphenyl Compounds; Insulin Resistance; Janus Kinase 2; Mal | 2010 |
Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2011 |
Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARγ target gene regulation.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Co | 2012 |
Effects of tempol and candesartan on neural control of the kidney.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biph | 2012 |
Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction.
Topics: Adipocytes; Aldosterone; Animals; Benzimidazoles; Biphenyl Compounds; Calcineurin; Cells, Cultured; | 2012 |
Angioedema associated with candesartan.
Topics: Angioedema; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Hypersensitivity; Fema | 2002 |
Renal angiotensin II type-2 receptors are upregulated and mediate the candesartan-induced natriuresis/diuresis in obese Zucker rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2005 |
Chronic candesartan alters expression and activity of NKCC2, NCC, and ENaC in the obese Zucker rat.
Topics: Amiloride; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Bipheny | 2008 |
Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Carotid Artery, Commo | 2001 |